No connection

Search Results

ARCT vs HITI

ARCT
Arcturus Therapeutics Holdings Inc.
BEARISH
Price
$6.68
Market Cap
$189.9M
Sector
Healthcare
AI Confidence
85%
HITI
High Tide Inc.
BEARISH
Price
$2.33
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ARCT
--
HITI
--
Forward P/E
ARCT
-1.61
HITI
16.47
P/B Ratio
ARCT
0.89
HITI
3.23
P/S Ratio
ARCT
2.31
HITI
0.33
EV/EBITDA
ARCT
0.22
HITI
10.1

Profitability

Gross Margin
ARCT
-36.79%
HITI
25.8%
Operating Margin
ARCT
-435.06%
HITI
2.32%
Profit Margin
ARCT
-80.19%
HITI
-7.42%
ROE
ARCT
-28.92%
HITI
-39.72%
ROA
ARCT
-15.5%
HITI
3.87%

Growth

Revenue Growth
ARCT
-68.4%
HITI
25.2%
Earnings Growth
ARCT
--
HITI
--

Financial Health

Debt/Equity
ARCT
0.12
HITI
1.1
Current Ratio
ARCT
6.64
HITI
1.43
Quick Ratio
ARCT
6.5
HITI
0.49

Dividends

Dividend Yield
ARCT
--
HITI
--
Payout Ratio
ARCT
0.0%
HITI
0.0%

AI Verdict

ARCT BEARISH

ARCT exhibits severe financial distress despite a modest insider sentiment score and analyst buy consensus. The Piotroski F-Score of 0/9 signals extreme financial weakness, with no positive indicators in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative margins, declining revenue, and negative earnings suggest high distress risk. While the stock trades below its 52-week high, its 5-year decline of 87.2% and persistent losses underscore deep operational challenges. The Graham Number and intrinsic value are unavailable, indicating no reliable fundamental floor, and the current price reflects speculative expectations rather than sustainable value.

Strengths
Analyst consensus is 'buy' with a target price of $23.44, implying significant upside potential
Insider sentiment is moderately positive at 40/100, suggesting some confidence in long-term prospects
Strong liquidity with a current ratio of 6.64 and quick ratio of 6.50, indicating robust short-term financial health
Risks
Piotroski F-Score of 0/9 indicates extreme financial instability and operational failure across all nine criteria
Revenue declined 68.4% YoY, signaling a severe contraction in business activity
Negative profit margins across all measures: -80.19% (net), -435.06% (operating), -36.79% (gross)
HITI BEARISH

HITI exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 25.20% and analysts maintain a 'strong_buy' rating with a target of $5.67, these are contradicted by a 0/100 technical trend and a negative profit margin of -7.42%. The disconnect between analyst optimism and the deterministic health scores suggests a high-risk speculative play rather than a value investment. The company's inability to convert revenue growth into consistent net income remains the primary concern.

Strengths
Strong YoY revenue growth of 25.20%
Positive operating margin of 2.32% suggesting core business viability
Very low Price/Sales ratio (0.33) indicating potential undervaluation of assets
Risks
Critical financial health (Piotroski F-Score 2/9)
Severe technical bearishness (Technical Trend 0/100)
Poor liquidity for immediate obligations (Quick Ratio 0.49)

Compare Another Pair

ARCT vs HITI: Head-to-Head Comparison

This page compares Arcturus Therapeutics Holdings Inc. (ARCT) and High Tide Inc. (HITI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile